Rhumbline Advisers Biocryst Pharmaceuticals Inc Transaction History

Rhumbline Advisers

  • $109 Billion
  • Q3 2024

A detailed history of Rhumbline Advisers transactions in Biocryst Pharmaceuticals Inc stock. As of the latest transaction made, Rhumbline Advisers holds 303,517 shares of BCRX stock, worth $2.21 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
303,517
Previous 318,665 4.75%
Holding current value
$2.21 Million
Previous $1.97 Million 17.12%
% of portfolio
0.0%
Previous 0.0%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024
SELL
$6.41 - $8.69 $97,098 - $131,636
-15,148 Reduced 4.75%
303,517 $2.31 Million
Q2 2024

Aug 01, 2024
BUY
$4.13 - $6.79 $78,123 - $128,439
18,916 Added 6.31%
318,665 $1.97 Million
Q1 2024

May 09, 2024
BUY
$4.89 - $7.65 $24,929 - $38,999
5,098 Added 1.73%
299,749 $1.52 Million
Q4 2023

Feb 08, 2024
SELL
$4.98 - $6.77 $3,406 - $4,630
-684 Reduced 0.23%
294,651 $1.76 Million
Q3 2023

Nov 09, 2023
SELL
$6.71 - $7.92 $124,530 - $146,987
-18,559 Reduced 5.91%
295,335 $2.09 Million
Q2 2023

Aug 08, 2023
BUY
$6.96 - $8.81 $19,662 - $24,888
2,825 Added 0.91%
313,894 $2.21 Million
Q1 2023

May 11, 2023
BUY
$7.94 - $11.84 $20,151 - $30,049
2,538 Added 0.82%
311,069 $2.59 Million
Q4 2022

Feb 14, 2023
BUY
$10.5 - $14.2 $99,550 - $134,630
9,481 Added 3.17%
308,531 $3.54 Million
Q3 2022

Nov 10, 2022
BUY
$10.79 - $14.81 $214,181 - $293,978
19,850 Added 7.11%
299,050 $3.77 Million
Q2 2022

Aug 11, 2022
SELL
$7.89 - $17.88 $90,103 - $204,189
-11,420 Reduced 3.93%
279,200 $2.95 Million
Q1 2022

May 12, 2022
SELL
$11.56 - $19.76 $261,810 - $447,524
-22,648 Reduced 7.23%
290,620 $4.73 Million
Q4 2021

Feb 10, 2022
BUY
$11.18 - $15.46 $28,050 - $38,789
2,509 Added 0.81%
313,268 $4.34 Million
Q3 2021

Nov 12, 2021
BUY
$14.21 - $17.65 $105,850 - $131,474
7,449 Added 2.46%
310,759 $4.47 Million
Q2 2021

Aug 05, 2021
BUY
$9.5 - $17.24 $350,008 - $635,173
36,843 Added 13.83%
303,310 $4.8 Million
Q1 2021

May 06, 2021
SELL
$7.37 - $13.61 $235,987 - $435,792
-32,020 Reduced 10.73%
266,467 $2.71 Million
Q4 2020

Feb 10, 2021
BUY
$3.37 - $8.61 $111,183 - $284,061
32,992 Added 12.43%
298,487 $2.22 Million
Q3 2020

Nov 12, 2020
SELL
$3.43 - $5.53 $36,886 - $59,469
-10,754 Reduced 3.89%
265,495 $912,000
Q2 2020

Aug 13, 2020
BUY
$1.9 - $5.61 $166,327 - $491,105
87,541 Added 46.39%
276,249 $1.32 Million
Q1 2020

May 06, 2020
BUY
$1.6 - $4.11 $7,262 - $18,655
4,539 Added 2.46%
188,708 $377,000
Q4 2019

Feb 05, 2020
BUY
$1.59 - $3.45 $14,480 - $31,419
9,107 Added 5.2%
184,169 $635,000
Q3 2019

Oct 23, 2019
BUY
$2.5 - $3.73 $34,077 - $50,843
13,631 Added 8.44%
175,062 $502,000
Q2 2019

Aug 14, 2019
BUY
$2.91 - $9.15 $34,617 - $108,848
11,896 Added 7.96%
161,431 $612,000
Q1 2019

May 01, 2019
SELL
$7.38 - $9.72 $2,501 - $3,295
-339 Reduced 0.23%
149,535 $1.22 Million
Q4 2018

Jan 31, 2019
BUY
$6.51 - $9.6 $363,186 - $535,574
55,789 Added 59.3%
149,874 $1.21 Million
Q3 2018

Nov 07, 2018
SELL
$5.52 - $7.99 $4,940 - $7,151
-895 Reduced 0.94%
94,085 $718,000
Q2 2018

Aug 06, 2018
BUY
$4.6 - $6.52 $14,880 - $21,092
3,235 Added 3.53%
94,980 $544,000
Q1 2018

May 02, 2018
BUY
$4.35 - $5.82 $43,282 - $57,909
9,950 Added 12.16%
91,745 $438,000
Q4 2017

Feb 09, 2018
SELL
$4.16 - $5.33 $56,838 - $72,823
-13,663 Reduced 14.31%
81,795 $402,000
Q3 2017

Nov 06, 2017
BUY
$4.1 - $5.97 $391,377 - $569,884
95,458
95,458 $500,000

Others Institutions Holding BCRX

# of Institutions
280
Shares Held
172M
Call Options Held
625K
Put Options Held
739K
View Full List

About BIOCRYST PHARMACEUTICALS INC

BCRX Quotes by TradingView
  • Ticker BCRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 185,944,992
  • Market Cap $1.35B
  • Description
  • BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat...
More about BCRX
Track This Portfolio

Track Rhumbline Advisers Portfolio

Follow Rhumbline Advisers and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

News

Stay updated on Rhumbline Advisers with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email